Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.27 (
AMPK
)
6,299
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
As an innovative CXC chemokine,
CXCL17
has a mysterious clinical significance and modulating influence on hepatocellular carcinoma (HCC). Our study examined the activity and mechanisms of
CXCL17
on growth, autophagy, and metastasis of HCC. Upregulation of
CXCL17
expression was observed in HCC, which is correlated with poorer histological stages and outcomes. Elevation of
CXCL17
expression promoted proliferation, invasion, and migration and decreased LC-3B biosynthesis and p62 protein reduction, which are known to stimulate autophagy. However, silencing of
CXCL17
inhibited the development of these cancerous phenotypes. Furthermore,
AMPK
was stimulated after knockdown of
CXCL17
. This stimulation, as well as stimulation of autophagy was caused by liver kinase B1 (LKB1), whose function is induced by knockdown
CXCL17
. Additionally, knockdown of
CXCL17
enhanced nuclear translocation of LKB1. Altogether, these findings suggest that elevated
CXCL17
expression in HCC promotes malignant reactions in malignant cells. Our research offers new evidence that chemokine
CXCL17
reinforces malignant invasion and suppresses autophagy via the LKB1-
AMPK
pathway.
...
PMID:CXCL17 promotes cell metastasis and inhibits autophagy via the LKB1-AMPK pathway in hepatocellular carcinoma. 3059 37